TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/26/2025
Back to search
Official data from USPTO
BICYCLE TUMOR-TARGETED IMMUNE CELL AGONIST
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
BICYCLE TUMOR-TARGETED IMMUNE CELL AGONIST
ST13
US500000079301041Class
5, 42
Filing
79301041
Registration
6624273
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
35
Latest update
04/02/2025
Trademark type
Word
Nice classes
5, 42
Filing date
10/27/2020
Registration date
01/25/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/25/2022
Last transaction
04/02/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
GB
Examiner
DAVIS, MARC
Law office
N40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Bicycletx Limited
Bicycletx Limited
Representatives
Christina M. Licursi Wolf, Greenfield & Sacks, P.C.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical productspharmaceutical preparations for use in oncology for both solid and liquid tumorsmetabolic diseaseurology and renal diseasecardiovascularhematologyrespiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disorders; pharmaceutical preparations for use as diagnosticsdiagnostic preparations for medical use and for use as clinical imaging agents
Class 42
Scientific and technological services and research and design relating theretoscientific researchnew product design servicesnew study design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumorsmetabolic diseaseurology and renal diseasecardiovascularhematologyrespiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disordersdiagnostic preparations and clinical imaging agents; industrial analysis and research services in the fields of oncology for both solid and liquid tumorsmetabolic diseaseurology and renal diseasecardiovascularhematologyrespiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disordersdiagnostic preparations and clinical imaging agents; informationconsultancy and advisory services relating to the aforesaid
Publications
History of USPTO decisions and trademark events.
35 publications found
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
03/26/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/26/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/26/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/26/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/26/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/01/2023
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
09/24/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/01/2022
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
07/02/2022
XXCR
GENERIC MADRID TRANSACTION CREATED
07/02/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/25/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
01/25/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/09/2021
PUBO
PUBLISHED FOR OPPOSITION
11/09/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/20/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/05/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/22/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/21/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/21/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
09/21/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/21/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/21/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/21/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
09/21/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/17/2021
RFNT
REFUSAL PROCESSED BY IB
04/25/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/05/2021
RFRR
REFUSAL PROCESSED BY MPU
04/05/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/30/2021
CNRT
NON-FINAL ACTION WRITTEN
03/29/2021
DOCK
ASSIGNED TO EXAMINER
03/28/2021
MAFR
APPLICATION FILING RECEIPT MAILED
01/06/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/02/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/31/2020
Continuous trademark protection
Get notified about every new filing that threatens BICYCLE TUMOR-TARGETED IMMUNE CELL AGONIST or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.